XTL Biopharmaceuticals LTD (XTLB) stock

Add to watchlist

Add holding +

NASDAQ: XTLB Nasdaq Biotechnology

XTL Biopharmaceuticals LTD is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

XTL Biopharmaceuticals LTD valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

Funds2 adding, 5 cuttingOf 0 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

Loss-making. Operating margin is -171.8%: costs exceed revenue.
Burning cash. Free cash flow was -370.7% of revenue over the last 12 months.
Heavy stock-based pay. Stock pay equals 58.5% of revenue: a real cost that cash-flow figures leave out.
Share dilution. Diluted shares rose 33.2% in a year.
Missing expectations. Earnings per share fell short of the consensus estimate in 3 of the last four quarters.

Latest results

Earnings per share: -$0.04 against an average estimate of $0.00: beat by 0.0%

XTL Biopharmaceuticals' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

1 day+5.6%
1 week-6.6%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM): $451,000
Operating margin: -171.8%
Net margin: -227.7%
EPS (TTM, diluted): $-0.78

Growth

Share count change: +33.2%

Cash

Free cash flow (TTM): -$1.7M
FCF margin: -370.7%
Stock pay % of revenue: 58.5%

News & updates

Updated November 2, 2026

Company announcements, filed results and changes that matter to shareholders.

No recent updates are available for XTLB from the sources we follow. See filings →

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

XTL Biopharmaceuticals LTD valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for XTL Biopharmaceuticals LTD: too few analysts cover it.

Earnings against estimates

XTL Biopharmaceuticals LTD: reported EPS against the consensus estimate
Quarter to	Estimate	Actual	Surprise
Mar 2016	$0.00	−$0.04	0.0%
Dec 2015	$0.00	−$0.06	0.0%
Sept 2015	−$0.20	−$0.02	+90.0%
Jun 2015	$0.00	−$0.02	0.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Positioning

Short interest: 0.2%
Days to cover: 0.51
Short interest, 1 month: −42%
Held by institutions: 0%
Held by insiders: 21.4%
Employees: 4

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Price behaviour

52-week range: Not enough history
From 52-week high: —
vs 50-day average: —
vs 200-day average: —
Volatility (1 year): —
Beta vs S&P 500: —

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 20-F, 20-F/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

XTL Biopharmaceuticals LTD: annual financial statements
Fiscal year	2024 Dec 2024
Income
Revenue	451
Gross profit	3
EBITDA	−576
Operating income	−775
Net income	−1,027
Margins
Gross margin	0.7%
EBITDA margin	−127.7%
Operating margin	−171.8%
Net margin	−227.7%
Free-cash-flow margin	−370.7%
Cash flow
Cash from operations	−1,618
Capital spending	54
Free cash flow	−1,672
Stock-based pay	264
Free cash flow after stock pay	−1,936
Balance sheet
Cash	371
Total debt	138
Net debt (negative = net cash)	−233
Diluted shares	7m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

0 of 1 checks passed · December 31, 2025

Short-term assets cover short-term liabilities The company doesn't report a short-term split. Not assessable.
Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Operating income of −$2m against $7,000 of interest.

From XTL Biopharmaceuticals LTD's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count: +33.2%; year over year
R&D spending: 3.5%; of revenue

Competitors: side by side with peers

Closest by revenue in biotechnology

Growth, margins and cash generation against peers
Last 12 months unless stated	XTLB	CRDF	CRVO	MNOV	STTK	CLNN	Median
Revenue, last 12 months	$451000	$508000	$331295	$920481	$1m	$197000	$55m
Revenue growth, last 12 months	—	−7.0%	−95.7%	875.7%	−66.6%	−31.1%	12.6%
Revenue growth, 3-year average	—	7.2%	−52.7%	—	5.2%	−36.9%	13.7%
Revenue growth, latest quarter	—	−14.0%	−100.0%	240.6%	−66.6%	233.3%	10.2%
Gross margin	0.7%	100.0%	100.0%	100.0%	—	70.1%	82.8%
Operating margin	−171.8%	<−999%	<−999%	<−999%	<−999%	<−999%	−187.2%
Operating margin, 3-year average	—	<−999%	<−999%	−905.8%	<−999%	<−999%	−363.5%
Net margin	−227.7%	<−999%	<−999%	<−999%	<−999%	<−999%	−172.8%
Cash from operations / revenue	−358.8%	<−999%	<−999%	−989.7%	<−999%	<−999%	−168.8%
Free-cash-flow margin	−370.7%	<−999%	—	−991.2%	<−999%	<−999%	−168.1%
Free-cash-flow margin, 3-year average	—	<−999%	—	<−999%	<−999%	<−999%	−310.0%
Stock pay / revenue	58.5%	>999%	393.0%	100.3%	853.2%	>999%	20.7%
Change in share count	33.2%	15.8%	8.4%	0.2%	15.3%	35.4%	8.3%

Median of all 185 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Who owns it

Funds buying and selling

Reported value: $20,652
Institutions reporting: 3
Shares held vs prior quarter: ▼ 89.6%
Positions opened / closed: 1 / 4

2 bought 5 sold

Top buyers and sellers, Q2 2026: 2 institutions bought and 5 sold ; the biggest buyer was Rhumbline Advisers (+241 shares) and the biggest seller Noked Israel Ltd (−50K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager	Value	Shares	Share of 13F value	Shares QoQ
Rhumbline Advisers	$17,000	6K	82.3%	▲ 4.0%
Gamma Investing LLC	$3,311	1K	16.0%	▼ 64.2%
UBS Group AG	$341	0K	1.7%	New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not XTL Biopharmaceuticals LTD's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart

Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders

Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

6-K REPORT OF FOREIGN PRIVATE ISSUER October 14, 2026
6-K REPORT OF FOREIGN PRIVATE ISSUER August 5, 2026
6-K REPORT OF FOREIGN PRIVATE ISSUER July 21, 2026
20-F ANNUAL REPORT June 30, 2026
6-K REPORT OF FOREIGN PRIVATE ISSUER June 30, 2026
6-K REPORT OF FOREIGN PRIVATE ISSUER June 29, 2026
6-K REPORT OF FOREIGN PRIVATE ISSUER June 23, 2026
6-K REPORT OF FOREIGN PRIVATE ISSUER May 22, 2026

Data status

When each part of this page on XTL Biopharmaceuticals LTD was last updated.

Data	Last updated	Source
Share price	November 2, 2026	Exchange closing prices
News and updates	November 2, 2026, 8:09am ET	Company releases and SEC 8-K filings
Analyst estimates	November 2, 2026, 7:33am ET	Aggregated analyst estimates
Valuation and scores	November 3, 2026, 9:41am ET	Our models, from the filed figures

How we build and check these figures: methodology and data sources.

XTL Biopharmaceuticals LTD in brief

What does XTL Biopharmaceuticals LTD do?: XTL Biopharmaceuticals LTD is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is XTL Biopharmaceuticals LTD's stock ticker?: XTL Biopharmaceuticals LTD trades under the ticker XTLB on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is XTL Biopharmaceuticals LTD's free cash flow?: XTL Biopharmaceuticals LTD's free-cash-flow margin is -370.7% of revenue over the trailing twelve months.
Who are XTL Biopharmaceuticals LTD's largest institutional shareholders?: By value reported in 13F filings for June 30, 2026, the largest reported holders are Rhumbline Advisers, Gamma Investing LLC and UBS Group AG. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Who are XTL Biopharmaceuticals LTD's competitors?: In our Biotechnology peer group, the companies closest to XTL Biopharmaceuticals LTD are Cardiff Oncology, Inc., Cervomed Inc., Medicinova Inc, Shattuck Labs, Inc. and Clene Inc. The side-by-side comparison below sets their revenue, margins and growth against XTL Biopharmaceuticals LTD's.